Hybridtides - a new class of therapeutic
John Gledhill
Lead Scientst, Longevity Biotech
Hybridtides are a new class of therapeutic which incorporate non-natural amino acids. Hybridtides overcome the challenges of targeting complex protein-protein interfaces for medicinal use. The discreet recognition of these interfaces are crucial in the treatment of many diseases. To date, traditional small molecule approaches have not been able to therapeutically modulate these interfaces due to the extended surface area and complex interactions. The specific non-natural amino acids we use along with the proprietary way in which we use them lead to a dramatic improvement in digestive resistance. The representative data on our targets pages suggest that significantly improved half-lives can be achieved while retaining the necessary biological activity.